STELARA (Ustekinumab) Research Report 2022: A Treatment for Adults with Moderately to Severe Active Crohn's Disease and Ulcerative Colitis - Drug Insight and Market Forecasts to 2032 - ResearchAndMarkets.com
27 Dec 2022
Drug ApprovalBiosimilar
DUBLIN--(BUSINESS WIRE)--The "STELARA (Ustekinumab), Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
'STELARA (Ustekinumab), Drug Insight and Market Forecast - 2032'
"STELARA (Ustekinumab), Drug Insight and Market Forecast - 2032" report provides comprehensive insights about STELARA (Ustekinumab) for Crohn's disease (CD) in the 7MM. A detailed picture of the STELARA (Ustekinumab) for Crohn's disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the STELARA (Ustekinumab) for Crohn's disease (CD).
The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the STELARA (Ustekinumab) market forecast, analysis for Crohn's disease (CD) in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Crohn's disease (CD).
Drug Summary
STELARA (Ustekinumab) is a prescription medicine approved for the treatment of adults 18 years and older with moderately to severely active Crohn's disease and Ulcerative Colitis.
There are many different naturally occurring proteins in the body that contribute to inflammation. Patients with Crohn's disease and Ulcerative Colitis are found to have elevated levels of two of these proteins, IL-12 and IL-23. STELARA is the FDA-approved medicine that targets IL-12 and IL-23, which are thought to be associated with gastrointestinal inflammation in Crohn's disease and Ulcerative Colitis.
STELARA is a human IgG1-k monoclonal antibody, is a human interleukin-12 and -23 antagonist. Using DNA recombinant technology, ustekinumab is produced in a murine cell line (Sp2/0). The manufacturing process contains steps for the clearance of viruses. Ustekinumab is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons.
Mechanism of Action
Ustekinumab is a human IgG1k monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. In in vitro models, ustekinumab was shown to disrupt IL-12 and IL-23 mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12Rk1.
The cytokines IL-12 and IL-23 have been implicated as important contributors to the chronic inflammation that is a hallmark of Crohn's disease and ulcerative colitis. In animal models of colitis, genetic absence or antibody blockade of the p40 subunit of IL-12 and IL-23, the target of ustekinumab, was shown to be protective.
STELARA (Ustekinumab) Clinical Assessment
The report provides the clinical trials information of STELARA (Ustekinumab) in Crohn's disease (CD) covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
In the coming years, the market scenario for Crohn's disease (CD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence STELARA (Ustekinumab) dominance.
Other emerging products for Crohn's disease (CD) are expected to give tough market competition to STELARA (Ustekinumab) and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of STELARA (Ustekinumab) in Crohn's disease (CD).
Our in-depth analysis of the forecasted sales data of STELARA (Ustekinumab) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the STELARA (Ustekinumab) in Crohn's disease (CD).
Key Questions Answered
What is the product type, route of administration and mechanism of action of STELARA (Ustekinumab)?
What is the clinical trial status of the study related to STELARA (Ustekinumab) in Crohn's disease (CD) and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the STELARA (Ustekinumab) development?
What are the key designations that have been granted to STELARA (Ustekinumab) for Crohn's disease (CD)?
What is the forecasted market scenario of STELARA (Ustekinumab) for Crohn's disease (CD)?
What are the forecasted sales of STELARA (Ustekinumab) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available in Crohn's disease (CD) and how are they giving competition to STELARA (Ustekinumab) for Crohn's disease (CD)?
Which are the late-stage emerging therapies under development for the treatment of Crohn's disease (CD)?
Key Topics Covered:
1. Report Introduction
2. STELARA (Ustekinumab) Overview
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical Studies
2.2.2. Clinical Trials Information
2.2.3. Safety and Efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. STELARA (Ustekinumab)Market Assessment
5.1. Market Outlook of STELARA (Ustekinumab) in Crohn's Disease (CD)
5.2. 7MM Market Analysis
5.2.1. Market Size of STELARA (Ustekinumab) in the 7MM for Crohn's Disease (CD)
5.3. Country-wise Market Analysis
5.3.1. Market Size of STELARA (Ustekinumab) in the United States for Crohn's Disease (CD)
5.3.2. Market Size of STELARA (Ustekinumab) in Germany for Crohn's Disease (CD)
5.3.3. Market Size of STELARA (Ustekinumab) in France for Crohn's Disease (CD)
5.3.4. Market Size of STELARA (Ustekinumab) in Italy for Crohn's Disease (CD)
5.3.5. Market Size of STELARA (Ustekinumab) in Spain for Crohn's Disease (CD)
5.3.6. Market Size of STELARA (Ustekinumab) in the United Kingdom for Crohn's Disease (CD)
5.3.7. Market Size of STELARA (Ustekinumab) in Japan for Crohn's Disease (CD)
6. SWOT Analysis
7. Analysts' Views
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/hizb2o
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.